All In Biotech

Drug Trial Radar · NCT04518410

ACTIV-2: A Study for Outpatients With COVID-19

Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)

Last checked: Nov 20, 2026Latest source record: Aug 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,044 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,044

Actual

Start

Aug 19, 2020

Primary completion

Apr 7, 2022

Study completion Jun 20, 2023

Sponsor

Sponsor type
NIH
Collaborators
Eli Lilly and Company; Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Brii Biosciences Limited; AstraZeneca; Sagent Pharmaceuticals; Synairgen Research Ltd.; Bristol-Myers Squibb; SAb Biotherapeutics, Inc.
First posted
Aug 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Drug studies often look at the effect one or two drugs have on a medical condition, and involve one company. There is currently an urgent need for one study to efficiently test multiple drugs from more than one company, in people who have tested positive for COVID-19 but who do not currently need hospitalization. This could help prevent disease progression to more serious symptoms and complications, and spread of COVID-19 in the community. This study looks at the safety and effectiveness of different drugs in treating COVID-19 in outpatients. In Phase II, participants in the study will be treated with either a study drug or with placebo. In protocol version 7.0, participants in Phase III of the study will be treated with either a study drug or active comparator drug. Participants assigned to the bamlanivimab agent/placebo arm and will have 28 days of intensive follow-up following study drug administration, followed by limited follow-up through 24 weeks in phase II and in phase III. All other investigational agents and their corresponding placebo arms will involve 28 days of intensive follow-up, followed by limited follow-up through 72 weeks in phase II and phase III. Additional study visits may be required, depending on the agent.

Conditions

  • Coronavirus
  • Covid19

Interventions

  • bamlanivimab 7000mgBiological

    Administered by single IV infusion. Participants are no longer being randomized to this intervention.

  • BRII-196+BRII-198Biological

    1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.

  • AZD7442 (IV)Biological

    300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.

  • AZD7442 (IM)Biological

    Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.

  • SNG001Drug

    1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.

  • CamostatDrug

    200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.

  • BMS-986414 + BMS-986413Biological

    Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg). Participants are no longer being randomized to this intervention.

  • SAB-185 (3,840 Units/kg)Biological

    Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.

  • SAB-185 (10,240 Units/kg)Biological

    Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.

  • CASIRIVIMAB + IMDEVIMABDrug

    600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry. Participants are no longer being randomized to this intervention.

  • Placebo for Bamlanivimab 7000mgDrug

    Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.

  • Placebo for Bamlanivimab 700mgDrug

    Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.

  • Placebo for BRII-196+BRII-198Drug

    Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.

  • Placebo for SNG001Drug

    Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device). Participants are no longer being randomized to this intervention.

  • Placebo for CamostatDrug

    200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.

  • Placebo for SAB-185 (low dose)Drug

    Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.

  • Placebo for BMS-986414 + BMS-986413Drug

    Administered SC as 4 separate injections for one dose. Participants are no longer being randomized to this intervention.

  • Placebo for AZD7442 (IV)Drug

    Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.

  • Placebo for AZD7442 (IM)Drug

    Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.

  • Placebo for SAB-185 (high dose)Drug

    Commercially available 0.9% sodium chloride solution. Participants are no longer being randomized to this intervention.

  • bamlanivimab 700mgBiological

    Administered by single IV infusion. Participants are no longer being randomized to this intervention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. COVID-19 Symptom Duration (Phase 2)Time frame: Up to Day 28
  2. Quantification of SARS-CoV-2 RNA (Phase 2)Time frame: Day 3
  3. Quantification of SARS-CoV-2 RNA (Phase 2)Time frame: Day 7
  4. Quantification of SARS-CoV-2 RNA (Phase 2)Time frame: Day 14
  5. Number of Participants With New Adverse Event (AE) ≥ Grade 3 (Phase 2)Time frame: Thru Day 28
  6. Cumulative Incidence of Death Due to Any Cause or Hospitalization Due to Any Cause (Phase 3)Time frame: Thru Day 28
  7. Proportion of Participants With New Adverse Event (AE) ≥ Grade 3 (Phase 3)Time frame: Thru Day 28

Locations

252 sites in 9 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group (Site 1082), 321 E. 10th Street

    Anniston, Alabama

  • North Alabama Research Center LLC (Site 1194), 721 W. Market St., Ste. B

    Athens, Alabama

  • University of Alabama at Birmingham (Site 1005), 908 20th Street South

    Birmingham, Alabama

  • Cullman Clinical Trials (Site 1140), 501 Clark St. NE.

    Cullman, Alabama

  • Jasper Summit Research, LLC. (Site 1056), 1280 Summit

    Jasper, Alabama

  • Absolute Clinical Research, LLC. (Site 1186), 7725 North 43rd Avenue, Ste. 211

    Phoenix, Arizona

  • University of Arizona (Site 1043), 1501 N. Campbell Ave., Rm. 6410

    Tucson, Arizona

  • Omnibus Clinical Research (Site 1253), 3340 W. Ball Road, Ste. I

    Anaheim, California

  • Franco A. Felizarta MD (Site 1174), 3535 San Dimas St.

    Bakersfield, California

  • Clearview Medical Research LLC. (Site 1251), 2714 Hidaway Ave., Ste. 103

    Canyon Country, California

  • St. Jude Heritage Medical Group (Site 1093), 2151 N. Harbor Blvd.

    Fullerton, California

  • University of California San Diego (Site 1160), 9350 Campus Point Drive, Perlman Cancer Cancer

    La Jolla, California

  • Fadi A. Haddad, MD, Inc. (Site 1146), 8860 Center Dr., Ste. 320

    La Mesa, California

  • Atella Clinical Research (Site 1111), 5451 La Palma Avenue

    La Palma, California

  • Loma Linda University Health (Site 1110), 11374 Mountain View, Dover Bldg, Ste. C

    Loma Linda, California

  • University of Southern California (Site 1057), 1300 N. Mission Rd., Rm 349

    Los Angeles, California

  • UCLA CARE Center (Site 1003), 11075 Santa Monica Blvd., Suite 100

    Los Angeles, California

  • Science 37, Inc. (Site 1124), 12121 Bluff Creek Dr., Ste. 100

    Los Angeles, California

  • VA Northern California Health Care System (NAVREF) (Site 1137), 10535 Hospital Way

    Mather, California

  • Central Valley Research, LLC (Site 1085), 400 E. Orangeburg Ave., Ste. 5

    Modesto, California

  • Hoag Memorial Hospital Presbyterian (Site 1200), 1 Hoag Dr.

    Newport Beach, California

  • Valley Clinical Research, Inc. (Site 1059), 18433 Roscoe Blvd., Ste 210

    Northridge, California

  • University of California Irvine (Site 1083), 843 Health Sciences Road

    Orange, California

  • FOMAT Medical Research (Site 1136), 300 South A Street

    Oxnard, California

  • Eisenhower Medical Center (Site 1040), 39000 Bob Hope Drive

    Rancho Mirage, California

  • Paradigm Research (Site 1150), 3652 Eureka Way

    Redding, California

  • Riverside Medical Clinic (Site 1232), 7117 Brockton Ave.

    Riverside, California

  • University of California Davis Medical Center (Site 1097), 2315 Stockton Blvd.

    Sacramento, California

  • Premier Urgent Care Centers of California, Inc. (Site 1176), 284 E. Highland Ave.

    San Bernardino, California

  • University of California San Diego (Site 1002), 220 Dickinson Street

    San Diego, California

  • Zion Medical Center (Site 1063), 4647 Zion Avenue

    San Diego, California

  • VA San Diego Health System (Stie 1127), 3350 La Jolla

    San Diego, California

  • University of California San Francisco (Site 1009), 995 Potrero Ave., Building 80, Ward 84

    San Francisco, California

  • San Francisco Research Institute (Site 1210), 2435 Ocean Ave.

    San Francisco, California

  • Stanford University (Site 1213), 1201 Welch Road

    Stanford, California

  • Millennium Clinical Trials (Site 1260), 550 Saint Charles Dr., Ste. 208

    Thousand Oaks, California

  • Office of Ramesh V. Nathan, MD (Site 1073), 2220 Lynn Rd., Ste. 301

    Thousand Oaks, California

  • Harbor UCLA (Site 1022), 1124 West Carson Street

    Torrance, California

  • Allianz Research Institute Inc. (Site 1159), 14120 Beach Blvd., Ste. 101

    Westminster, California

  • University of Colorado (Site 1007), 12401 East 17th Avenue

    Aurora, Colorado

Showing 40 of 252 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.